SCHEMBL4096410

SCHEMBL4096410

CCOC(=O)N1CCN(c2nc(C3CCCCC3)nc3ccc(OC)cc23)CC1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NTSR1 P30989 12/20 0.59
ALDH1A1 P00352 3/20 0.50
MAPT P10636 2/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.50
IDE P14735 1/20 0.50
HPGD P15428 1/20 0.50
HIF1A Q16665 1/20 0.50
MTNR1B P49286 3/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
PAX8 Q06710 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MTNR1A P48039 1/20 0.46
NOS3 P29474 1/20 0.45
NOS1 P29475 1/20 0.45
NOS2 P35228 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4090980 0.88 NTSR1 (0.63) NTSR1ALDH1A1MAPTKDM4ELMNA
SCHEMBL4094967 0.88 IDE (0.50) NTSR1ALDH1A1MAPTKDM4ELMNA
SCHEMBL4096402 0.84 NTSR1 (0.70) NTSR1ALDH1A1MAPTKDM4ELMNA
SCHEMBL4095451 0.83 NTSR1 (0.69) NTSR1ALDH1A1MAPTKDM4ELMNA
SCHEMBL4753784 0.81 NTSR1 (0.61) NTSR1ALDH1A1MAPTKDM4ELMNA
SCHEMBL4097266 0.76 MAPT (0.59) NTSR1ALDH1A1MAPTKDM4ELMNA
SCHEMBL4085061 0.76 MEN1 (0.53) NTSR1ALDH1A1MAPTKDM4ELMNA
SCHEMBL4085268 0.76 MAPT (0.52) NTSR1ALDH1A1MAPTKDM4ELMNA
SCHEMBL4088982 0.75 NTSR1 (0.70) NTSR1ALDH1A1MAPTKDM4ELMNA
SCHEMBL15819562 0.75 NTSR1 (1.00) NTSR1ALDH1A1MAPTKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 NTSR1 337/4885ALDH1A1 4857/4885MAPT 4125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.